Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Emerson Bernardes; Peter Caravan; R Michael van Dam; Winnie Deuther-Conrad; Beverley Ellis; Shozo Furumoto; Benjamin Guillet; Ya-Yao Huang; Hongmei Jia; Peter Laverman; Zijing Li; Zhaofei Liu; Filippo Lodi; Yubin Miao; Lars Perk; Ralf Schirrmacher; Johnny Vercoullie; Hua Yang; Min Yang; Xing Yang; Junbo Zhang; Ming-Rong Zhang; Hua Zhu

doi:10.1186/s41181-022-00162-3

Highlight selection of radiochemistry and radiopharmacy developments by editorial board

EJNMMI Radiopharm Chem. 2022 Apr 26;7(1):9. doi: 10.1186/s41181-022-00162-3.

Authors

Emerson Bernardes¹, Peter Caravan², R Michael van Dam³, Winnie Deuther-Conrad^{4

5}, Beverley Ellis⁶, Shozo Furumoto⁷, Benjamin Guillet⁸, Ya-Yao Huang⁹, Hongmei Jia¹⁰, Peter Laverman¹¹, Zijing Li¹², Zhaofei Liu¹³, Filippo Lodi¹⁴, Yubin Miao¹⁵, Lars Perk¹⁶, Ralf Schirrmacher¹¹, Johnny Vercoullie¹⁷, Hua Yang¹⁸, Min Yang¹⁹, Xing Yang²⁰, Junbo Zhang¹⁰, Ming-Rong Zhang²¹, Hua Zhu²²

Affiliations

¹ IPEN, São Paulo, Brazil.
² Massuchusetts General Hospital, Harvard University, Cambridge, USA.
³ University of California, Los Angeles, Los Angeles, USA.
⁴ Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany. w.deuther-conrad@hzdr.de.
⁵ Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. w.deuther-conrad@hzdr.de.
⁶ Manchester University NHS Foundation Trust, Manchester, UK.
⁷ CYRIC, Tohoku University, Sendai, Japan.
⁸ CERIMED, C2VN, Aix-Marseille Univ, Marseille, France.
⁹ National Taiwan University College of Medicine, Taipei, Taiwan.
¹⁰ Beijing Normal University, Beijing, China.
¹¹ University of Alberta, Edmonton, Canada.
¹² Xiamen University, Xiamen, China.
¹³ Peking University, Beijing, China.
¹⁴ S. Orsola-Malpighi Hospital, Bologna, Italy.
¹⁵ University of Colorado, Denver, USA.
¹⁶ Radboud University Medical Center, Nijmegen, The Netherlands.
¹⁷ University of Tours, Tours, France.
¹⁸ TRIUMF, Vancouver, Canada.
¹⁹ Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, People's Republic of China.
²⁰ Peking University First Hospital, Beijing, China.
²¹ NIRS, Chiba, Japan.
²² Peking University Cancer Hospital, Beijing, China.

Abstract

Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

Results: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included.

Conclusion: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Keywords: Highlights; Radiochemistry; Radiopharmacy; Review.

Publication types

Review

Abstract

Publication types

Grants and funding